Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas

EGFR analyses allow for better correlation between genotype and phenotype in astrocytomas and represent an attractive therapeutic target. Most studies emphasize analyses of EGFR in glioblastomas (GBMs) but do not analyze all grades of astrocytomas (from pilocytic to GBM). The purpose of our study wa...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of biological markers 2014-06, Vol.29 (2), p.e120-128
Main Authors: Carvalho, Priscila O, Uno, Miyuki, Oba-Shinjo, Sueli M, Rosemberg, Sergio, Wakamatsu, Alda, da Silva, Clemar C, Teixeira, Manoel J, Marie, Suely K N
Format: Article
Language:English
Subjects:
Adult
Astrocytoma - enzymology
Astrocytoma - genetics
Astrocytoma - pathology
Astrocytoma - therapy
Brain Neoplasms - enzymology
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Female
Glioblastoma - enzymology
Glioblastoma - genetics
Glioblastoma - pathology
Glioblastoma - therapy
Humans
Male
Receptor, Epidermal Growth Factor - metabolism
Signal Transduction
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:EGFR analyses allow for better correlation between genotype and phenotype in astrocytomas and represent an attractive therapeutic target. Most studies emphasize analyses of EGFR in glioblastomas (GBMs) but do not analyze all grades of astrocytomas (from pilocytic to GBM). The purpose of our study was to evaluate the status of EGFR (expression, deletion, and amplification) and EGFR protein expression in all grades of astrocytomas. We analyzed a total of 145 surgical tumor specimens that included: 22 pilocytic astrocytomas, 22 grade II astrocytomas, 17 grade III astrocytomas and 84 GBMs. The specimens were compared to 17 non-neoplastic brain tissues obtained from epilepsy surgery. EGFR expression, EGFR amplification and EGFRvIII analyses were performed by quantitative real-time PCR, and protein expression was evaluated by immunohistochemistry. EGFR relative overexpression and EGFR amplification were observed, respectively, in 50% and 20% of astrocytomas, while EGFRvIII was only found in GBMs (34.5%, p=0.005). Amongst EGFR-amplified GBM cases, 59% also presented EGFRvIII (p
ISSN:1724-6008
1724-6008
DOI:10.5301/JBM.5000045